BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 17707239)

  • 1. PET and PET/CT in pediatric oncology.
    Jadvar H; Connolly LP; Fahey FH; Shulkin BL
    Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
    Chen Z; Li X; Li F; Ouyang Q; Yu T
    Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
    Hallett WA; Maguire RP; McCarthy TJ; Schmidt ME; Young H
    IDrugs; 2007 Nov; 10(11):791-6. PubMed ID: 17968761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions.
    Shammas A; Lim R; Charron M
    Radiographics; 2009; 29(5):1467-86. PubMed ID: 19755606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT in pediatric oncology.
    Samuel AM
    Indian J Cancer; 2010; 47(4):360-70. PubMed ID: 21131747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT in diagnostic oncology.
    Messa C; Bettinardi V; Picchio M; Pelosi E; Landoni C; Gianolli L; Gilardi MC; Fazio F
    Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):66-75. PubMed ID: 15243404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring cancer treatment with PET/CT: does it make a difference?
    Weber WA; Figlin R
    J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
    Czernin J; Allen-Auerbach M; Schelbert HR
    J Nucl Med; 2007 Jan; 48 Suppl 1():78S-88S. PubMed ID: 17204723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of PET and PET/CT in pediatric malignancies.
    Kumar R; Shandal V; Shamim SA; Halanaik D; Malhotra A
    Expert Rev Anticancer Ther; 2010 May; 10(5):755-68. PubMed ID: 20470007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
    Israel O; Kuten A
    J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fever of unknown origin: the role of 18F-FDG PET/CT.
    Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
    J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.
    Tian J; Yang X; Yu L; Chen P; Xin J; Ma L; Feng H; Tan Y; Zhao Z; Wu W
    J Nucl Med; 2008 Feb; 49(2):186-94. PubMed ID: 18199618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/CT in malignant bone disease.
    Even-Sapir E
    Semin Musculoskelet Radiol; 2007 Dec; 11(4):312-21. PubMed ID: 18324596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.